Kamada Q2 Revenue Beats by 8%, Reaffirms 2026 Outlook
KMDA is trading near its 52-week low of $6.5 (11% above the low).
Summary
Kamada reported record-high first half and second quarter 2026 financial results, with Q2 revenue of $54.9M beating the $50.66M consensus by 8%, driven by strong KEDRAB sales in the U.S. and growth in VARIZIG and HEPAGAM. Adjusted EBITDA rose 29% YoY, and the company reaffirmed full-year 2026 guidance of $200M-$205M revenue and $50M-$53M adjusted EBITDA. The results represent double-digit profitable growth and the strongest in Kamada's history. This follows the July plasma supply agreement and positive CYTOGAM data, reinforcing commercial momentum. The stock trades at 13x forward earnings, well below the $13 median price target.
At the time of this announcement, KMDA was trading at $7.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $409.1M. The 52-week trading range was $6.50 to $9.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.